• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology and IKE Tech Applaud FDA Crackdown, Call for Tech-Driven Enforcement to Prevent Illicit Trade and Protect Youth

    11/17/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    LOS ANGELES, Nov. 17, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), an innovator in vaping technology and precision dosing, and IKE Tech LLC ("IKE Tech"), a joint venture that includes Ispire as a founding partner, released statements following the U.S. Food and Drug Administration's (FDA) Congressional funding and directive to combat the illicit vape market.

    Ispire (PRNewsfoto/Ispire Technology Inc.)

    As part of the continuing resolution passed by Congress and signed by President Trump, the FDA is now required to allocate at least $200 million of its $712 million in user fees toward enforcing regulations on electronic nicotine delivery systems (ENDS). This includes $2 million to support a multi-agency task force — involving the Departments of Justice and Homeland Security — focused on removing illegal ENDS products entering the U.S. from abroad. The FDA must also update its 2020 enforcement guidance to address flavored disposable vapes and report to Congress twice yearly on its progress.

    John Patterson, president of IKE Tech, said:

    Today's enforcement push is a wake-up call for an industry that's lost control of its own standards. When nine out of ten vapes on shelves are illegal, it's clear that reactive border controls and paper-based tracking mechanisms aren't working. We commend the U.S. Congress and FDA for taking decisive action to clean up a market that's been flooded with unregulated products that are exposing users – especially youth – to potential harms.

    IKE Tech and our JV partners are building the technological backbone for these efforts; from blockchain-secured smart authentication tags that enable real-time product tracing at every step of the supply chain, to AI-driven interoperable age-verification solutions that ensure only verified adults can activate a device. Together, these tools can help border agents, regulators and manufacturers verify product legitimacy instantly, reinforcing compliance, combating counterfeits and keeping illegal imports out of U.S. markets.

    This is the kind of built-in security that can finally align regulators, manufacturers and consumers around the shared goal of public safety and youth prevention.

    Michael Wang, co-CEO of Ispire Technology, added:

    The FDA's renewed crackdown is the right move, but reactive enforcement must be paired with proactive technological standards. Illicit imports don't only erode FDA authority, they distort enforcement, overwhelm legitimate supply chains and make it challenging for responsible and compliant companies to compete. To win the fight, we must invest in technology that delivers dual security across the market, including new tools to verify product legitimacy at the point of use.

    Ispire and IKE Tech's blockchain-powered, FDA-submitted age-verification chip delivers real-time identity validation at the device level, ensuring only verified adults can activate a vape, not just purchase one. By pairing enforcement with innovation, we can rebuild trust, protect youth and bring the $30 billion flavored vape market back under lawful, responsible control.

    Both Ispire and IKE Tech emphasized that the FDA's strengthened enforcement mandate represents a vital first step, but one that must be paired with proactive, technology-based solutions that prevent illicit products proliferating the market, while securing devices from misuse before they reach consumers. Their jointly developed blockchain-enabled System-on-a-Chip, submitted to the FDA earlier this year as part of a Pre-Market Tobacco Product Application (PMTA), offers a path toward verifiable, interoperable compliance across the industry.

    About IKE Tech LLC

    IKE Tech LLC ("IKE Tech") is pioneering real-time identity verification and product authentication, helping to safeguard access to age-restricted products.

    Founded in 2024, IKE Tech is building the identity layer for the physical world. With patented technologies spanning blockchain authentication, secure BLE communication, and AI-enhanced access control, IKE Tech powers secure, user-centric device interactions across regulated and high-risk sectors.

    IKE Tech's interoperable Bluetooth Low Energy (BLE) System-on-a-Chip, powered by a user-friendly mobile app available on iOS and Android, integrates seamlessly into ENDS devices, giving manufacturers and regulators a flexible, future-proofed solution to combat underage vaping and illicit markets. By setting the new standard for responsible, adult-only access, IKE Tech is helping eliminate youth vaping for good.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, X and YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    IR Contacts:

    KCSA Strategic Communications

    Phil Carlson

    212.896.1233

    [email protected]

    PR Contact:

    Ellen Mellody

    570.209.2947

    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-technology-and-ike-tech-applaud-fda-crackdown-call-for-tech-driven-enforcement-to-prevent-illicit-trade-and-protect-youth-302616654.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Unveils Next-Gen Cannabis Hardware Ecosystem at MJBizCon 2025

    Company to Showcase Fully Reengineered Portfolio; Executive Team, Including Head of Sales John Monds, Available for On-Site Meetings LOS ANGELES, Nov. 26, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire," or the "Company"), announced that it will unveil its fully reengineered cannabis product ecosystem at MJBizCon 2025, the world's largest cannabis industry conference and trade show. Held December 2–5 at the Las Vegas Convention Center, the event will serve as the official launchpad for Ispire's next-generation hardware suite. At the heart of this launch is

    11/26/25 5:34:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology and IKE Tech Applaud FDA Crackdown, Call for Tech-Driven Enforcement to Prevent Illicit Trade and Protect Youth

    LOS ANGELES, Nov. 17, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), an innovator in vaping technology and precision dosing, and IKE Tech LLC ("IKE Tech"), a joint venture that includes Ispire as a founding partner, released statements following the U.S. Food and Drug Administration's (FDA) Congressional funding and directive to combat the illicit vape market. As part of the continuing resolution passed by Congress and signed by President Trump, the FDA is now required to allocate at least $200 million of its $712 million in user fees to

    11/17/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fargis John sold $14,625 worth of shares (7,500 units at $1.95), decreasing direct ownership by 16% to 39,099 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    11/24/25 4:30:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 29,784 shares, increasing direct ownership by 142% to 50,782 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:31:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    6/26/25 4:30:08 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Key Leadership Appointments

    LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

    8/14/23 8:35:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care